Endocrinology and Metabolism

Editorial

Miscellaneous
Forty Years Together, New Leap Forward! The 40th Anniversary of the Korean Endocrine Society: Jong Chul Won, Ki-Hyun Baek; Endocrinol Metab. 2022;37(6):851-857. Published online December 26, 2022; DOI: https://doi.org/10.3803/EnM.2022.604

1,425 View
165 Download

PDF PubReader ePub

Review Articles

Diabetes
The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes: Gwang Sil Kim, Joong Hyun Park, Jong Chul Won; Endocrinol Metab. 2019;34(2):106-116. Published online May 9, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.2.106

5,211 View
101 Download
15 Web of Science
14 Crossref

Abstract PDF PubReader ePub

The prevalence of type 2 diabetes mellitus (T2DM), which is associated with cardiovascular morbidity and mortality, is increasing worldwide. Although there have been advances in diabetes treatments that reduce microvascular complications (nephropathy, neuropathy, retinopathy), many clinical studies have found that conventional oral hypoglycemic agents and glucose control alone failed to reduce cardiovascular disease. Thus, incretin-based therapies including glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2Is) represent a new area of research, and may serve as novel therapeutics for treating hyperglycemia and modifying other cardiovascular risk factors. Recently, it has been confirmed that several drugs in these classes, including canagliflozin, empagliflozin, semaglutide, and liraglutide, are safe and possess cardioprotective effects. We review the most recent cardiovascular outcome trials on GLP-1RAs and SGLT-2Is, and discuss their implications for treating patients with T2DM in terms of protective effects against cardiovascular disease.

Citations

Citations to this article as recorded by

Switch to gliflozins and biventricular function improvement in patients with chronic heart failure and diabetes mellitus
Michele Correale, Pietro Mazzeo, Martino Fortunato, Matteo Paradiso, Andrea Furore, Angela I. Fanizzi, Lucia Tricarico, Giuseppe Pastore, Simona Alfieri, Natale D. Brunetti, Olga Lamacchia
Clinical Physiology and Functional Imaging.2024; 44(1): 112. CrossRef
Association between underweight and risk of heart failure in diabetes patients
Tae Kyung Yoo, Kyung‐Do Han, Eun‐Jung Rhee, Won‐Young Lee
Journal of Cachexia, Sarcopenia and Muscle.2024; 15(2): 671. CrossRef
Paradigm Shift in Management of Hyperglycemia in Patients with Type 2 Diabetes: Glucocentric versus Organ Protection
Jong Chul Won
The Journal of Korean Diabetes.2023; 24(2): 59. CrossRef
Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies
Braden Millar, Monica de Gaetano
Frontiers in Pharmacology.2023;[Epub] CrossRef
Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study
Paolo Basile, Andrea Igoren Guaricci, Giuseppina Piazzolla, Sara Volpe, Alfredo Vozza, Marina Benedetto, Maria Cristina Carella, Daniela Santoro, Francesco Monitillo, Andrea Baggiano, Saima Mushtaq, Laura Fusini, Fabio Fazzari, Cinzia Forleo, Nunziata Rib
Journal of Clinical Medicine.2023; 12(4): 1586. CrossRef
Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN‐HF study
Michele Correale, Elena‐Laura Antohi, Riccardo M. Inciardi, Pietro Mazzeo, Stefano Coiro, Shiro Ishihara, Renata Petroni, Francesco Monitillo, Marta Leone, Marco Triggiani, Chaudhry M.S. Sarwar, Hans‐Dirk Dungen, Khawaja M. Talha, Natale D. Brunetti, Jave
ESC Heart Failure.2023; 10(3): 2066. CrossRef
Effects of Incretin-Based Treatment on the Diastolic (Dys)Function in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Study with 1-Year Follow-Up
Elena-Daniela Grigorescu, Cristina-Mihaela Lăcătușu, Mariana Floria, Georgiana-Diana Cazac, Alina Onofriescu, Livia-Amira Sauciuc, Alexandr Ceasovschih, Ioana Crețu, Bogdan-Mircea Mihai, Laurențiu Șorodoc
Diagnostics.2023; 13(17): 2817. CrossRef
Role of moesin in the effect of glucagon-like peptide-1 on advanced glycation end products-induced endothelial barrier dysfunction
Yan Liu, Zhenzhen Chen, Lei Liu, Haitao Tang, Huaqing Zhu, Songtao Tang
Cellular Signalling.2022; 90: 110193. CrossRef
Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Diabetes Therapy.2021; 12(1): 171. CrossRef
Effectiveness of liraglutide 3 mg for the treatment of obesity in a real-world setting without intensive lifestyle intervention
Jung Ha Park, Ju Young Kim, Jong Han Choi, Hye Soon Park, Hyun-Young Shin, Jae Min Lee, Jin-Wook Kim, Hae-Jin Ko, Suk Chon, Bu Kyung Kim, Chul Sik Kim, Soo Lim
International Journal of Obesity.2021; 45(4): 776. CrossRef
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
Shruti S Joshi, Trisha Singh, David E Newby, Jagdeep Singh
Heart.2021; 107(13): 1032. CrossRef
Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis
Da-Peng Zhang, Li Xu, Le-Feng Wang, Hong-Jiang Wang, Feng Jiang
Cardiovascular Diabetology.2020;[Epub] CrossRef
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee
Clinical and Molecular Hepatology.2020; 26(4): 430. CrossRef
Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
Kohei Kaku, Koichi Kisanuki, Mari Shibata, Takashi Oohira
Drug Safety.2019; 42(11): 1311. CrossRef

Obesity and Metabolism
Recent Advances in Diagnostic Strategies for Diabetic Peripheral Neuropathy: Jong Chul Won, Tae Sun Park; Endocrinol Metab. 2016;31(2):230-238. Published online May 27, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.2.230

7,683 View
131 Download
51 Web of Science
54 Crossref

Abstract PDF PubReader

Diabetes is an increasing epidemic in Korea, and associated diabetic peripheral neuropathy (DPN) is its most common and disabling complication. DPN has an insidious onset and heterogeneous clinical manifestations, making it difficult to detect high-risk patients of DPN. Early diagnosis is recommended and is the key factor for a better prognosis and preventing diabetic foot ulcers, amputation, or disability. However, diagnostic tests for DPN are not clearly established because of the various pathophysiology developing from the nerve injury to clinical manifestations, differences in mechanisms according to the type of diabetes, comorbidities, and the unclear natural history of DPN. Therefore, DPN remains a challenge for physicians to screen, diagnose, follow up, and evaluate for treatment response. In this review, diagnosing DPN using various methods to assess clinical symptoms and/or signs, sensorineural impairment, and nerve conduction studies will be discussed. Clinicians should rely on established modalities and utilize current available testing as complementary to specific clinical situations.

Citations

Citations to this article as recorded by

The Relationship Between UA/HDL and Diabetic Peripheral Neuropathy: A Cross-Sectional Analysis
Ruoxi Zhen, Shuqi Wang, Shuchun Chen
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 969. CrossRef
Role of Regenerative Therapeutics in Diabetic Peripheral Neuropathy: Current Advances and Future Prospects
Sanjay Sharma, Ravi Velamoor Rangarajan
European Journal of Medical and Health Sciences.2024; 6(2): 1. CrossRef
Understanding the Clinical Relationship Between Diabetic Retinopathy, Nephropathy, and Neuropathy: A Comprehensive Review
Aditi Kulkarni, Archana R Thool, Sachin Daigavane
Cureus.2024;[Epub] CrossRef
DSPNet: A Self-ONN Model for Robust DSPN Diagnosis From Temperature Maps
Amith Khandakar, Muhammad E. H. Chowdhury, Mamun Bin Ibne Reaz, Serkan Kiranyaz, Anwarul Hasan, Tawsifur Rahman, Sawal Hamid Md. Ali, Mohd Ibrahim bin Shapiai @ Abd. Razak, Ahmad Ashrif A. Bakar, Kanchon Kanti Podder, Moajjem Hossain Chowdhury, Md. Ahasan
IEEE Sensors Journal.2023; 23(5): 5370. CrossRef
A Machine Learning-Based Severity Prediction Tool for the Michigan Neuropathy Screening Instrument
Fahmida Haque, Mamun B. I. Reaz, Muhammad E. H. Chowdhury, Mohd Ibrahim bin Shapiai, Rayaz A. Malik, Mohammed Alhatou, Syoji Kobashi, Iffat Ara, Sawal H. M. Ali, Ahmad A. A. Bakar, Mohammad Arif Sobhan Bhuiyan
Diagnostics.2023; 13(2): 264. CrossRef
Screening for diabetic peripheral neuropathy in resource-limited settings
Ken Munene Nkonge, Dennis Karani Nkonge, Teresa Njeri Nkonge
Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef
Assessment of Lumbosacral Nerve Roots in Patients with Type 2 Diabetic Peripheral Neuropathy Using Diffusion Tensor Imaging
He Chen, Yanyan Xu, Wei Wang, Ruifen Deng, Zhaoqing Li, Sheng Xie, Jinsong Jiao
Brain Sciences.2023; 13(5): 828. CrossRef
Evidence of impaired H-reflex and H-reflex rate-dependent depression in diabetes, prediabetes and obesity: a mini-review
Rebeca Kababie-Ameo, Gabriela Gutiérrez-Salmeán, Carlos A. Cuellar
Frontiers in Endocrinology.2023;[Epub] CrossRef
The effect of polyneuropathy severity on nerve conduction and pain syndrome in patients with type 2 diabetes
A.Ya. Sabovchyk, M.M. Oros
INTERNATIONAL NEUROLOGICAL JOURNAL.2023; 19(6): 161. CrossRef
Effects of Neural Mobilization in Diabetic Peripheral Neuropathy: A Scoping Review
Muhammad Azharuddin, Sarah Parveen, Majumi M. Noohu
Journal of Chiropractic Medicine.2023; 22(4): 313. CrossRef
Effect of massage, passive neural mobilization and transcutaneous electrical nerve stimulation on magnetic resonance diffusion tensor imaging (MR-DTI) of the tibial nerve in a patient with type 2 diabetes mellitus induced neuropathy: a case report
Goyal Manu, Mittal Amit, Samuel Asir John
Physiotherapy Theory and Practice.2022; 38(13): 3273. CrossRef
Diabetic corneal neuropathy as a surrogate marker for diabetic peripheral neuropathy
WeiZheng So, NatalieShi Qi Wong, HongChang Tan, MollyTzu Yu Lin, IsabelleXin Yu Lee, JodhbirS Mehta, Yu-Chi Liu
Neural Regeneration Research.2022; 17(10): 2172. CrossRef
SUDOSCAN in Combination with the Michigan Neuropathy Screening Instrument Is an Effective Tool for Screening Diabetic Peripheral Neuropathy
Tae Jung Oh, Yoojung Song, Hak Chul Jang, Sung Hee Choi
Diabetes & Metabolism Journal.2022; 46(2): 319. CrossRef
Performance Analysis of Conventional Machine Learning Algorithms for Diabetic Sensorimotor Polyneuropathy Severity Classification Using Nerve Conduction Studies
Fahmida Haque, Mamun B. I. Reaz, Muhammad E. H. Chowdhury, Serkan Kiranyaz, Sawal H. M. Ali, Mohammed Alhatou, Rumana Habib, Ahmad A. A. Bakar, Norhana Arsad, Geetika Srivastava, Paolo Crippa
Computational Intelligence and Neuroscience.2022; 2022: 1. CrossRef
The Presence of Clonal Hematopoiesis Is Negatively Associated with Diabetic Peripheral Neuropathy in Type 2 Diabetes
Tae Jung Oh, Han Song, Youngil Koh, Sung Hee Choi
Endocrinology and Metabolism.2022; 37(2): 243. CrossRef
Advances in traditional Chinese medicine as adjuvant therapy for diabetic foot
Fa-Shun Liu, Yue Li, Xian-Shan Guo, Rui-Chen Liu, Hong-Ya Zhang, Zhen Li
World Journal of Diabetes.2022; 13(10): 851. CrossRef
Magnitude of diabetic peripheral neuropathy in Saudi Arabia: a systematic review and meta-analysis
Lukman Femi Owolabi, Mushabab Alghamdi, Bappa Adamu, Magaji Garba Taura, Abubakar Jibo, Mohammed Almansour, Saeed Naseer Alaklabi, Mohammed Ali Alghamdi, Yousef Ayesh Alotaibi, Isa Adamu Imam, Reda Abdelrazak, Ahmad Rafaat, Muktar Hassan Aliyu
BMC Endocrine Disorders.2022;[Epub] CrossRef
Artificial Intelligence Methodologies Applied to Technologies for Screening, Diagnosis and Care of the Diabetic Foot: A Narrative Review
Gaetano Chemello, Benedetta Salvatori, Micaela Morettini, Andrea Tura
Biosensors.2022; 12(11): 985. CrossRef
Diabetic foot ulcer: Challenges and future
Li Yang, Gui-Chuan Rong, Qi-Nan Wu
World Journal of Diabetes.2022; 13(12): 1014. CrossRef
A review of the current evidence on the sensitivity and specificity of the Ipswich touch test for the screening of loss of protective sensation in patients with diabetes mellitus
Arnold Hu, Beatrice Koh, Melissa- Raye Teo
Diabetology International.2021; 12(2): 145. CrossRef
Prevalence of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus at a tertiary referral centre in Singapore
Arnold Hu Hanquan, Melissa-Raye Teo Li Wen
Proceedings of Singapore Healthcare.2021; 30(4): 265. CrossRef
Performance Analysis of Conventional Machine Learning Algorithms for Diabetic Sensorimotor Polyneuropathy Severity Classification
Fahmida Haque, Mamun Bin Ibne Reaz, Muhammad Enamul Hoque Chowdhury, Geetika Srivastava, Sawal Hamid Md Ali, Ahmad Ashrif A. Bakar, Mohammad Arif Sobhan Bhuiyan
Diagnostics.2021; 11(5): 801. CrossRef
Thai version of the Questionnaire for Diabetes-Related Foot Disease (Thai Q-DFD): validity and reliability
Rapeepun Thungtak, Jirabhorn Wannapakhe, Saitida Lapanantasin
Heliyon.2021; 7(8): e07832. CrossRef
A nomogram-based diabetic sensorimotor polyneuropathy severity prediction using Michigan neuropathy screening instrumentations
Fahmida Haque, Mamun Bin Ibne Reaz, Muhammad E.H. Chowdhury, Sawal Hamid Md Ali, Ahmad Ashrif A Bakar, Tawsifur Rahman, Syoji Kobashi, Chitra A. Dhawale, Mohammad Arif Sobhan Bhuiyan
Computers in Biology and Medicine.2021; 139: 104954. CrossRef
Correlation Between Hemoglobin Glycosylation Index and Nerve Conduction Velocity in Patients with Type 2 Diabetes Mellitus
Zelin Li, Yuan Gao, Yujiao Jia, Shuchun Chen
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 4757. CrossRef
Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes
Kyuho Kim, Tae Jung Oh, Hyen Chung Cho, Yun Kyung Lee, Chang Ho Ahn, Bo Kyung Koo, Jae Hoon Moon, Sung Hee Choi, Hak Chul Jang
Scientific Reports.2021;[Epub] CrossRef
Standard clinical screening tests, sural radial amplitude ratio and f wave latency compared to conventional nerve conduction studies in the assessment of sensorimotor polyneuropathy in patients with type 2 diabetes mellitus
Saraswathi Ramanathan, Raji Thomas, AsemRangita Chanu, Dukhabandu Naik, Felix Jebasingh, Ajit Sivadasan, Nihal Thomas
Indian Journal of Endocrinology and Metabolism.2021; 25(6): 509. CrossRef
IFN‐γ/mTORC1 decreased Rab11 in Schwann cells of diabetic peripheral neuropathy, inhibiting cell proliferation via GLUT1 downregulation
Wei Du, Song Zhao, Fan Gao, Mengyu Wei, Jiahui An, Keqi Jia, Fan Li, Lin Zhu, Jun Hao
Journal of Cellular Physiology.2020; 235(7-8): 5764. CrossRef
Diagnosis and treatment of the early stages of diabetic polyneuropathy
V. N. Khramilin, A. N. Zavyalov, I. Yu. Demidova
Meditsinskiy sovet = Medical Council.2020; (7): 56. CrossRef
Diabetic Peripheral Neuropathy: Is it Underdiagnosed?
Rizaldy T. Pinzon, M. Kes, Rosa De Lima R. Sa
Asian Journal of Biological Sciences.2020; 13(2): 168. CrossRef
The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial
Yeek Tat Ng, Sonia Chew Wen Phang, Gerald Chen Jie Tan, En Yng Ng, Nevein Philip Botross Henien, Uma Devi M. Palanisamy, Badariah Ahmad, Khalid Abdul Kadir
Nutrients.2020; 12(5): 1522. CrossRef
Prevalence of diabetic peripheral neuropathy in Africa: a systematic review and meta-analysis
Wondimeneh Shibabaw Shiferaw, Tadesse Yirga Akalu, Yeshamble Work, Yared Asmare Aynalem
BMC Endocrine Disorders.2020;[Epub] CrossRef
Choosing a Vibratory Test to Pair With Semmes Weinstein Monofilament Testing for Evaluating Lower Extremity Sensation in Patients With Diabetes: A Comparison of Three Vibratory Methodologies
Bryan Raymond, James Steriovski, KaNesha Gillyard, Chalen Yang, Stephanie C. Wu, Ryan T. Crews
Journal of Diabetes Science and Technology.2020; 14(1): 8. CrossRef
Is it possible to substitute the monofilament test for the Ipswich Touch Test in screening for peripheral diabetic neuropathy?
Luz Marina Alfonso Dutra, Mirian Conceição Moura, Flaviene Alves do Prado, Giselle De Oliveira Lima, Manuela Costa Melo, Rubens Nelson Morato Fernandez, Maria Rita Carvalho Garbi Novaes
Diabetology & Metabolic Syndrome.2020;[Epub] CrossRef
Correlation Between Thioredoxin-Interacting Protein and Nerve Conduction Velocity in Patients With Type 2 Diabetes Mellitus
Yuan Gao, Shuchun Chen, Minmin Peng, Zi Wang, Luping Ren, Shumin Mu, Meiling Zheng
Frontiers in Neurology.2020;[Epub] CrossRef
Performance analysis of noninvasive electrophysiological methods for the assessment of diabetic sensorimotor polyneuropathy in clinical research: a systematic review and meta-analysis with trial sequential analysis
Fahmida Haque, Mamun Bin Ibne Reaz, Sawal Hamid Md Ali, Norhana Arsad, Muhammad Enamul Hoque Chowdhury
Scientific Reports.2020;[Epub] CrossRef
The impact of demographic and clinical characteristics on diabetic painful neuropathy
António Assunção, Dina Campos, Rui Marques, Inês Cunha, Patrícia Santos, Adriana Martins, Ana Sofia Gonçalves, Ana Rebelo, Carolina Lima, César Matos, Ana Cristina Prata, José Tiago Teixeira, Luís Duarte, Mariana Belo, Patrícia Figueiredo, Tiago Letras Ro
Romanian Journal of Internal Medicine.2020; 58(1): 13. CrossRef
Nanotechnology in peripheral nerve repair and reconstruction
Cristiana R. Carvalho, Joana Silva-Correia, Joaquim M. Oliveira, Rui L. Reis
Advanced Drug Delivery Reviews.2019; 148: 308. CrossRef
The risk factors for diabetic peripheral neuropathy: A meta-analysis
Xiuxiu Liu, Yuyan Xu, Miaomiao An, Qibing Zeng, Antonio Palazón-Bru
PLOS ONE.2019; 14(2): e0212574. CrossRef
Association between deterioration in muscle strength and peripheral neuropathy in people with diabetes
Tae Jung Oh, Sunyoung Kang, Jie-Eun Lee, Jae Hoon Moon, Sung Hee Choi, Soo Lim, Hak Chul Jang
Journal of Diabetes and its Complications.2019; 33(8): 598. CrossRef
Characterizing distal peripheral neuropathy in type 2 diabetes mellitus in a semi-urban community setting in Peru
Meera F Iyengar, Antonio Bernabe-Ortiz
Journal of Global Health Reports.2019;[Epub] CrossRef
A study protocol on nerve mobilization induced diffusion tensor imaging values in posterior tibial nerve in healthy controls and in patients with diabetic neuropathy-multigroup pretest posttest design
Manu Goyal, Vandana Esht, Amit Mittal
Contemporary Clinical Trials Communications.2019; 16: 100451. CrossRef
The Akt/mTOR cascade mediates high glucose-induced reductions in BDNF via DNMT1 in Schwann cells in diabetic peripheral neuropathy
Cui-Hong Zhang, Xin Lv, Wei Du, Mei-Juan Cheng, Ya-Ping Liu, Lin Zhu, Jun Hao
Experimental Cell Research.2019; 383(1): 111502. CrossRef
Transcriptome analysis of dorsal root ganglia's diabetic neuropathy reveals mechanisms involved in pain and regeneration
Maria Carolina Pedro Athie, Andre Schwambach Vieira, Juliana Maia Teixeira, Gilson Gonçalves dos Santos, Elayne Vieira Dias, Claudia Herrera Tambeli, Cesar Renato Sartori, Carlos A. Parada
Life Sciences.2018; 205: 54. CrossRef
Diagnosis and Management of Diabetic Peripheral Neuropathy
Seong-Su Moon
The Journal of Korean Diabetes.2018; 19(3): 153. CrossRef
Efficacy of epalrestat plus α-lipoic acid combination therapy versus monotherapy in patients with diabetic peripheral neuropathy: a meta-analysis of 20 randomized controlled trials
Ming Zhao, Jia-Yi Chen, Yu-Dong Chu, Ya-Bin Zhu, Lin Luo, Shi-Zhong Bu
Neural Regeneration Research.2018; 13(6): 1087. CrossRef
Interactions between and Shared Molecular Mechanisms of Diabetic Peripheral Neuropathy and Obstructive Sleep Apnea in Type 2 Diabetes Patients
Hong Shen, Junrong Zhao, Ying Liu, Guangdong Sun
Journal of Diabetes Research.2018; 2018: 1. CrossRef
Evaluation of the healthy median nerve elasticity
Bihui Zhu, Feng Yan, Ying He, Liyun Wang, Xi Xiang, Yuanjiao Tang, Yujia Yang, Li Qiu
Medicine.2018; 97(43): e12956. CrossRef
Association between thermal threshold abnormalities and peripheral artery disease in patients with type 2 diabetes
Yi-Jing Sheen, Tsai-Chung Li, Jiann-Liang Lin, Wen-Chen Tsai, Chuen-Der Kao, Cho-Tsan Bau, Wayne H.-H. Sheu
Medicine.2018; 97(51): e13803. CrossRef
Neurogenic Pain Disorder in the Foot and Ankle: Peripheral Neuropathy
Hak Jun Kim, Young Hwan Park, Soo Hyun Kim
Journal of the Korean Orthopaedic Association.2017; 52(4): 305. CrossRef
Diabetes-Related Microvascular Complications: What Every Nurse Practitioner Needs to Know
Eileen Egan
The Journal for Nurse Practitioners.2017; 13(3): 192. CrossRef
Comparison of electrochemical skin conductance and vibration perception threshold measurement in the detection of early diabetic neuropathy
Amit Goel, Channabasappa Shivaprasad, Anish Kolly, Vijaya Sarathi H. A., Sridevi Atluri, Rayaz Ahmed Malik
PLOS ONE.2017; 12(9): e0183973. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
Nailfold capillary abnormalities are associated with type 2 diabetes progression and correlated with peripheral neuropathy
Po-Chi Hsu, Pei-Yung Liao, Hen-Hong Chang, John Y. Chiang, Yu-Chuen Huang, Lun-Chien Lo
Medicine.2016; 95(52): e5714. CrossRef

Case Reports

A Case of Primary Hypothyroidism with Anti-Triiodothyronine Autoantibody.: Jae Ho Park, Ji Hoon Ahn, Mi Hee Kang, Jong Chul Won, Kyung Wook Lee, Yeo Joo Kim, Ji Oh Mok, Hyeong Kyu Park, Chul Hee Kim, Sang Jin Kim, Dong Won Byun, Kyo Il Suh, Myung Hi Yoo; J Korean Endocr Soc. 2006;21(5):428-432. Published online October 1, 2006; DOI: https://doi.org/10.3803/jkes.2006.21.5.428

1,857 View
24 Download
1 Crossref

Abstract PDF

Antithyroid hormone autoantibodies can be present in the sera of patients with thyroid and non-thyroid disorders. Antithyroid hormone autoantibodies in a patient's serum interfere with radioimmunoassay of thyroid hormones. Clinically, this interference can result in discordance between the serum thyroid hormone levels and the clinical features of the patient, which can lead to misdiagnosis or inappropriate treatment. We experienced a woman who had primary hypothyroidism with unexpectedly high concentrations of serum total triiodothyronine (T(3)) and free T(3), and she had been treated for Graves' disease in the past. Through the use of a polyethylene glycol precipitation method, we detected the anti-triiodothyronine autoantibodies in her serum. We report on this case along with a review of the related literature.

Citations

Citations to this article as recorded by

Thyroxine (T4) Autoantibody Interference of Free T4 Concentration Measurement in a Patient With Hashimoto’s Thyroiditis
Mi-Na Lee, Soo-Youn Lee, Kyu Yeon Hur, Hyung-Doo Park
Annals of Laboratory Medicine.2017; 37(2): 169. CrossRef

A Case of Hyperthyroidism Associated with Symptomatic Hypercalcemia.: Ju Hyun Choi, Woo Je Lee, Yun Hee Chung, Hye Won Park, Dan Bi Lee, Jong Chul Won, Duk Jae Kim, Ghi Su Kim; J Korean Endocr Soc. 2006;21(3):251-256. Published online June 1, 2006; DOI: https://doi.org/10.3803/jkes.2006.21.3.251

1,963 View
26 Download

Abstract PDF: Two of the common causes of hypercalcemia are malignancy and primary hyperparathyroidism. These disorders are easily diagnosed by the clinical manifestations and measurement of the serum intact parathyroid hormone (PTH) level. On the other hand, hyperthyroidism is an uncommon cause of hypercalcemia. The diagnosis of hypercalcemia associated with hyperthyroidism can only be made by excluding the common causes of hypercalcemia and by observing the improvement of the hypercalcemia and its associated symptoms with normalizing the thyroid function. Herein we reported our experience with a 67 year-old woman who presented with nausea and vomiting. She showed elevated serum calcium and phosphorus levels. Serum intact PTH level was 1.1 pg/mL (normal range; 10~65). The results of the thyroid function test were compatible with hyperthyroidism. After resolution of the thyrotoxicosis with combination treatment of methimazol and Lugol's solution, the patient's serum calcium and phosphorus levels were normalized and the symptoms were improved.

Original Articles

Percutaneous Ethanol Injection in Autonomous Functioning Thyroid Nodules and Complex Cysts: Five Years' Experience.: Seong Jin Lee, Jung Hee Han, Ha Young Kim, Jong Chul Won, Sang Wook Kim, Ho Kyu Lee, Il Min Ahn; J Korean Endocr Soc. 2002;17(1):57-68. Published online February 1, 2002

1,029 View
17 Download

Abstract PDF: BACKGROUND
Percutaneous ethanol injection therapy (PEI) performed with ultrasonography guidance has recently been used in cases of autonomous functioning thyroid nodules (AFTN) and benign complex cysts. We performed this study to analyze the effects of PEI on AFTN and benign complex cysts. METHEODS: From September 1995 to September 2000, we performed PEI on 456 outpatients (47 men and 409 women, mean age 42.4+/-11.8 years) with AFTN or benign complex cysts. All cases were subjected to fine needle aspirations (FNA) by ultrasonography-guidance if necessary. FNA was performed at least twice with results of colloid nodule in cases of complex cysts. For AFTN, cases with FNA results of follicular neoplasm were also included. After PEI on AFTN, patients were classified into three response groups: complete response as judged by our new criteria (CR, normalization of TSH and free T4, disappearance of hot nodule on thyroid scan) along with the old criteria of previous studies (normalization of TSH and free T4, recovery of suppressed extranodular tissue on thyroid scan), partial response (PR, normalized free T4 but suppressed TSH, persistent hot nodule despite recovery in suppressed extranodular tissue) and no response (no change of hot nodule). Complex cysts were classified into three groups in accordance with volume reduction after PEI: complete response (CR, above 90% of volume reduction), partial response (PR, 50~89%) and no response (below 50%). RESULTS: Overall pre-treatment volumes were 15.3+/-12.1 mL and post-treatment volumes were 2.8+/-2.9 mL, with 66.4+/-19.9% of volume reductions in AFTN and complex cysts. Volume reductions were 71.5+/-18.0% in AFTN, and 66.1+/-15.0% in complex cysts. In 24 cases of AFTN, responses satisfying the previous criteria were 14 (58.3%) of CR, 6 (25.0%) of PR, and 4 (16.7%) of no response. However, by the new criteria there were 1 (4.2%) of CR, 10 (41.6%) of PR, and 13 (54.2%) of no response. In 432 cases of complex cysts, CR was observed in 82 (19.0%), PR in 261 (60.4%) and no response in 89 (20.6%). The volume reductions in complex cysts with pre-treatment volume larger than 15 mL were higher than those of groups with smaller volumes (p<0.001). Pre-treatment volumes were not correlated with post-treatment volumes, nor with volume reductions. Volume reductions were not correlated with the amounts of injected ethanol. Mild and transient complications were observed in 41 cases (9.0%) during PEI, consisting of transient neck pain (n=36, 7.9%), transient unilateral vocal cord palsy (n=3, 0.7%), intracavitary hemorrhage (n=1, 0.2%), and transient hypotension (n=1, 0.2%). CONCLUSION: Our data suggest that the efficacy of PEI on AFTN is temporary and does not usually induce long-term complete remissions. In complex cysts, however, PEI may have potential as an additive treatment modality to thyroid hormone suppressive therapy

Clinical Applications of 18-FDG PET in Recurred Differentiated Thyroid Cancer with Negative 131I Whole Body Scintigraphy: A Comparative Analysis with 99mTc-MIBI Scintigraphy.: Jong Chul Won, Sung Jin Lee, Tae Yun Lee, Il Seong Nam-Goong, Sy Yeol Lee, Ha Young Kim, Jung Hee Han, Jin Sook Ryu, Dae Hyuk Moon, Il Min Ahn; J Korean Endocr Soc. 2001;16(4-5):481-493. Published online October 1, 2001

930 View
18 Download

Abstract PDF: BACKGROUND
In patients with differentiated thyroid cancer treated by surgery and radioactive iodine ablation, serum thyroglobulin(Tg) and 131I whole body scan(WBS) are recognized as being the best cooperative indicators for detection of recurrence or metastasis. However, in some cases, 131I WBS shows no specific lesions despite elevated serum Tg. Therefore, 18-Fluorine-fluorodeoxyglucose (FDG) positron emission tomography(PET) has emerged as a useful method for the detection of 131I WBS negative thyroid cancers. The aims of the present study are to evaluate the clinical usefulness of this technique in detection and to compare the results with 99mTc-MIBI scintigraphy(MIBI) in cases of final results being confirmed by histologic diagnosis and other imaging methods. METHODS: We conducted a retrospective analysis amon 131I WBS negative recurred papillary thyroid carcinoma patients(male: female ratio=9:22, median age=42 yr). FDG PET was performed in 28 patients and MIBI 28 patients, 25 of whom were common to both groups. All patients had histologically proven recurrence/metastasis and negative 131I WBS results but persistently elevated serum Tg levels. In each case overall clinical evaluations were performed including histology, cytology, thyroglobulin level, other imaging methods, posttherapy 131I WBS and subsequent clinical course, to allow comparison with the results of FDG PET. RESULTS: In 19 cases of patients with negative 131I WBS, proven recurrence/metastasis lesions were detected in FDG PET. Compared with MIBI, FDG PET was found to be superior in 8 cases(including 2 patients with distant metastases). No FDG-negative/MIBI-positive tumor was observed. One FDG PET negative and MIBI negative case was proven 3 months later to be metastatic cervical lymph nodes, Sensitivities were 94.7% in the FDG PET group and 52.6% in MIBI. Diagnostic accuracy of FDG PET was superior to that of MIBI(93% vs. 62%, respectively, p=0.003). CONCLUSION: Our results confirmed the clinical usefulness of FDG PET for detection of 131I negative differentiated thyroid cancers and suggested the value of FDG PET as an initial diagnostic step, rather than MIBI, in these cases.

Effectiveness of Percutaneous Ethanol Injection in Benign Cold Thyroid Nodules: Five Years' Experience.: Seong Jin Lee, Jung Hee Han, Ha Young Kim, Jong Chul Won, Sang Wook Kim, Ho Kyu Lee, Il Min Ahn; J Korean Endocr Soc. 2001;16(2):210-220. Published online April 1, 2001

1,028 View
17 Download

Abstract PDF: BACKGROUND
Percutaneous ethanol injection therapy (PEI) which is performed with the guidance of ultrasonography has recently been used in patient who had benign cold thyroid nodules. We performed this study to analyze the long-term effects of PEI on benign cold thyroid nodules. METHOD: From September 1995 to September 2000, we treated 198 outpatients (12 men and 186 women, who had a mean age of 40.8 years, with a range of 15-71) who had benign cold thyroid nodules at the Asan Medical Center. The PEI was performed on 141 patients who had solitary nodules (SN) and on 57 patients who had prominent nodules or Questionable or typing error? multiple nodules (MN). All patients had fine needle aspirations (FNAs) at least twice which resulted in a diagnosis of the presence of a colloid nodule. Thyroid hormone was given to all patients along with TSH measurements. The thyroid hormone dose was titrated to correspond to TSH level of a low normal range. These patients were followed up for mean period of 37.6 months (range 18-60). Patients who were treated with PEI were classified into three groups according to their volume reduction: a complete response (CR, which was above 90% in volume reduction), a partial response (PR, which was a 50-89%) reduction and No Response (which was below 50% or an increased size) groups. RESULTS: The overall pre-treatment volumes of the nodules were 15.7+/-19.8 mL. The overall post-treatment volumes were 2.4+/-2.6 mL and consisted of volume reductions of 70.1+/-17.1%. The results of PEI for all of the patients were: a complete reduction (CR) in 34 cases (17.2%), a partial reduction (PR) in 142 cases (71.7%) and No Response in 22 patients (11.1%). In 141 patients in the SN group, in which there was a mean follow-up duration of 36.7+/-11.2 months, the volume reductions were 68.3+/-18.8%. CR was observed in 20 patients (14.2%), PR in 103 (73.0%) and No Response in 18 (12.8%). In twenty-two of the SN patients (22/141, 15.6%) we were able to discontinue the thyroid hormone suppressive therapy because those nodules had markedly decreased in volume after PEI without any further increase of nodule size during the follow-up period. In 57 patients in the MN group, over a mean follow-up durations of 37.1+/-11.4 months, the volume reductions were 74.3+/-12.1%. CR was observed in 14 patients (24.6%), PR in 39 (68.4%) and No Response occurred in 4 (7.0%). During the follow-up period after PEI, further volume reductions were observed for 36 months after thyroid hormone suppressive therapy in the Response Group. Differences in volume reductions between the SN and MN groups were not statistically significant but the volume reductions in patients who had a pre-treatment volume larger than 15 mL were higher than those in the smaller group (p<0.001). In the cases of the SN and MN groups, volume reductions did not correlate with either the amount of injected ethanol or the pre-treatment volumes, but the pre-treatment volumes correlated with post-treatment volumes in the patients who had SN (p<0.001, r=0.411) and MN (p<0.001, r=0.729). We observed mild, but transient complications in 32 patients (16.2%) during PEI which included a transient neck pain (n=27, 13.6%), a transient unilateral vocal cord palsy (n=4, 2.0%), and an abscess formation (n=1, 0.5%) which was cured. CONCLUSION: These results suggest that PEI is a feasible adjunctive therapy to use in thyroid hormone suppressive therapy for benign cold thyroid nodules

Differential Diagnostic Value of TSH Receptor Antibody Measurements in Thyrotoxic Postpartum Patients with History of Graves' Disease.: Seong Jin Lee, Yun Ey Chung, Ha Young Kim, Jung Hee Han, Jong Chul Won, Ahm Kim, Jin Sook Ryu, Dae Hyuk Moon, Il Min Ahn; J Korean Endocr Soc. 2001;16(1):75-84. Published online February 1, 2001

1,110 View
20 Download

Abstract PDF: BACKGROUND
It is known that pregnancy markedly influences the clinical course of autoimmune thyroid diseases. In the postpartum period, various kinds of autoimmune thyroid dysfunctions can be observed. Thyroid dysfunction is found in 5.5-7.1% of postpartum women in the general population. Among those who show thyroid dysfunction after delivery, some will develop Graves' disease and others will develop postpartum thyroiditis. It is also known that patients with Graves' disease may manifest thyrotoxicosis in the postpartum period because of postpartum thyroiditis or relapse of the Graves' disease itself. We evaluated the clinical features of postpartum thyrotoxicosis in Graves' disease patients to find diagnostic indices that could be used in differentiating between postpartum thyroiditis and relapse of Graves' disease. METHOD: We reviewed the cases with postpartum thyrotoxicosis in patients that had a history of Graves' disease between 1995 and 2000. The diagnosis of postpartum thyroiditis had been made by means of a 99mTc thyroid scan or by the observation of a typical triphasic thyroid function change, in cases where a 99mTc thyroid scan was not possible because of breast feeding. We measured the serum TSH, free T4, free T3, TSH binding inhibiting immunoglobulin (TBII), anti-thyroid peroxidase (TPO) antibody, and anti- thyroglobulin (Tg) antibody serially from the time of the diagnosis of Graves' disease to the time of postpartum thyroid dysfunction. RESULTS: Eleven patients, 5 patients in the postpartum thyroiditis (PPT group) and 6 patients with relapse of the Graves' disease (GD group), were identified. The mean values of TBII of two groups at the time of diagnosis of Graves' disease were 40.9+/-4.8 IU/mL (PPT group), 58.9+/-23.5 IU/mL (GD group) respectively, which were insignificant. The mean values of TBII of the two groups at early pregnancy were 3.2+/-1.9 IU/mL (PPT group), 41.6+/-22.6 IU/mL (GD group) and this difference was statistically significant (p=0.009). The mean values of TBII of the two groups at the time of postpartum thyrotoxicosis were 1.9+/-1.6 IU/mL (PPT group), 51.5+/-23.2 IU/mL (GD group) which were also statistically significant (p=0.003). The mean values of anti-TPO antibody, anti-Tg antibody, disease duration, and treatment duration between the two groups were not significantly different. The onsets of thyroid dysfunction after delivery in the two groups were 2.6+/-2.0 (PPT group), 4.0+/-3.9 (GD group) months which were statistically insignificant. CONCLUSION: These data suggest that the measurement of TBII at the time of the postpartum thyrotoxic period, could help to differentiate postpartum thyroiditis from a relapse of Graves' disease in those patients that have a history of Graves' disease especially when thyroid scan is not possible because of breast feeding.

Lanreotide Therapy in Graves' Ophthalmopathy.: Il Seong Nam-Goong, Eun Ju Lee, Jung Hwoon Kim, Jong Chul Won, Woo jae Lee, Jung Hee Han, sung Jin Lee, Sang Wook Kim, Moo Kon Son, Ho Hye Lee, Il Min Ahn; J Korean Endocr Soc. 2001;16(1):18-25. Published online February 1, 2001

1,091 View
20 Download

Abstract PDF: BACKGROUND
Graves' ophthalmopathy (GO) is an autoimmune process that affects the orbital tissues. Patients with GO are usually treated with high doses of corticosteroids, retrobulbar irradiation, or by surgical decompression, however, those have some adverse effect. Recently, a synthetic somatostatin analogue has been reported for the treatment of GO. This study was performed prospectively to evaluate the therapeutic effects of lanreotide, a potent long acting synthetic somatostatin analogue, in patients that have GO. METHODS: Eight patients with moderate to severe GO (M:F=1:7, age 39.0+/-11.8 years) were included. Patients who had been treated with other modalities than GO, or had a systemic illness such as diabetes were excluded. Eight patients were given lanreotide, 40mg IM every 2 weeks over a period of 8 weeks. Their therapeutic responses were evaluated using an orbital CT or MRI and by ophthalmologic examinations. RESULTS: After 8 weeks' of lanreotide treatment, 4 patients showed decreased scores in the NOSPECS classification (p=0.059) as well as 5 patients in their clinical activity scores(p=0.109). All of the 8 patients showed improvements according to clinical evaluation criteria (p=0.008). Significant changes in the thickness of both the lateral rectus and superior rectus muscles were observed (p<0.05). No patient showed serious adverse effects related to lanreotide therapy during the follow-up periods. CONCLUSION: We conclude that lanreotide therapy has clinical benefits and show radiologic improvements in GO. Considering the minimal side-effects of lanreotide compared to those of corticosteroid, lanreotide therapy should be considered for use in selected patients that have Graves' ophthalmopathy

The Role of Preoperative and Postoperative Thyroglobulin Measurements in The Detection of Well Differentiated Thyroid Carcinomas Recurrence.: Seong Jin Lee, Jong Chul Won, Ha Young Kim, Jung Hee Han, Eun Ju Lee, Sang Wook Kim, Jin Sook Ryu, Dae Hyuk Moon, Suk Joon Hong, Il Min Ahn; J Korean Endocr Soc. 2000;15(4-5):542-553. Published online January 1, 2001

1,089 View
19 Download

Abstract PDF: BACKGROUND
Thyroglobulin (Tg) measurement is primarily used to monitor patients with well differentiated thyroid carcinomas (WDTC) for tumor recurrence. We evaluated the correlations between fold responses of thyroglobulin levels and TNM stages (and MACIS scores) at recurrent group. Also correlations between preoperative Tg levels and Tg (on or off replacement) levels at the time of recurrence were evaluated. Postoperative Tg levels between recurrent and non-recurrent groups were analyzed for the use of assessing risk of recurrence. METHODS: One hundred twenty five cases of WDTC who had total thyroidectomy and (131)I remnant thyroid ablation were finally included in this study. After optimal TSH stimulations (>30 microIU/mL), (131)I whole body scan (WBS) was performed. We interpreted as a recurrence only when abnormal findings on the (131)I WBS were detected. Preoperative, immediate postoperative and follow-up Tg tlevels were regularly measured. RESULTS: Difference of preoperative Tg levels between recurrent and non-recurrent groups was not significant (27.5+/-4.2 ng/mL vs. 16.0+/-10.9 ng/mL). Also differences of immediate postoperative Tg (on or off replacement) levels between two groups was not significant (2.4+/-3.8 ng/mL vs. 3.6+/-3.l ng/mL, 33.4+/-4.8 ng/ml vs. 24.5+/-4.8 ng/mL, respectively). Tg levels on replacement at 24 months after surgery between recurrent and non-recurrent groups were significantly different (2.2+/-4.8 ng/mL, 15.9+/-6.5 ng/mL, p<0.001) and also Tg levels off replacement between recurrent and non-recurrent groups were significantly different (4.0+/-6.6ng/mL vs. 49.4+/-9.3 ng/mL, p<0.001). Fold responses between recurrent and non-recurrent groups were significantly different (2.0+/-3.1 ng/mL, 5.0+/-4.1 ng/mL, p=0.009). Fold responses between recurrent and non- recurrent groups were significantly different according to TNM stages (p=0.002) but not different according to MACIS scores. Preoperative Tg levels were correlated Tg (on or off replacement) levels at the time of recurrence (p=0.02, r=0.4: p<0.001, r=0.6, respectively). Sensitivity, specificity, accuracy of Tg levels over 2 ng/mL on replacement were 95%, 73%, 84% but those of Tg levels over 7 ng/mL off replacement were 83%, 70%, 77%. CONCLUSION: Fold responses may predict prognosis of WDTC. Small postoperative increase in serum Tg levels may indicate a large increase of tumor mass in cases of normal or low preoperative Tg levels. Tg levels over 2 ng/mL on replacement or 7 ng/mL off replacement during follow-up may suggest the recurrence of WDTC.

Case Report

A Case of Ectopic ACTH Syndrome Caused by Thymic Carcinoid Tumor and Localized by PET.: Jong Chul Won, Sung Kwan Hong, Hyun Ju Lee, Sang Ook Kim, Yun Hee Jeong, Dae Hyuk Moon, Dong Kwan Kim, Kyung Yub Kong, Jae Sung Lee, Ki Soo Kim; J Korean Endocr Soc. 1999;14(4):771-778. Published online January 1, 2001

936 View
17 Download

Abstract PDF: Ectopic ACTH syndrome is frequently caused by lung cancer and uncommonly by other tumors such as thymic carcinoid. For its treatment, early diagnosis and complete resection is irresponsible, but some cases are remained unlocalized in spite of all diagnostic modalities. Here we report a case of ectopic ACTH syndrome which was localized by PET but could not be localized by conventional technique. A tumor at thymic area was ACTH secreting thymic carcinoid which was operated but couldnt resect completly. Glucocorticoid hypersecretion was persisted with chemotherapy, radiotherapy, and ketoconazole treatment. Patient died of sepsis after 12 months of diagnosis.

First
Prev
Page of 1
Next
Last

Search